Comparing Onset of Biosimilar Versus Generic Competition in the United States-Reference-Cited by-同舟云学术

Comparing Onset of Biosimilar Versus Generic Competition in the United States

Published:2020-08-17 Issue:6 Volume:108 Page:1308-1314
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Beall Reed F.¹²,Ronksley Paul E.¹,Wick James¹,Darrow Jonathan J.²,Sarpatwari Ameet²,Kesselheim Aaron S.²

Affiliation:

1. Department of Community Health Sciences O’Brien Institute of Public Health, Cummings School of Medicine University of Calgary Calgary Alberta Canada

2. Program On Regulation, Therapeutics, and Law (PORTAL) Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine Brigham and Women’s Hospital and Harvard Medical School Boston Massachusetts USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1981

Reference32 articles.

1. The High Cost of Prescription Drugs in the United States

2. Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court’s Recent Rulings do not Solve Fundamental Barriers to Competition

3. The high price of anticancer drugs: origins, implications, barriers, solutions

4. IQVIA Institute for Human Data Science.Medicine Use and Spending in the US: A Review of 2017 and Outlook to 2022 [Internet]. Parsippany (NJ): United States (2019). Accessed May 27 2020.

5. United States Food and Drug Administration.FDA/CDER SVIA Chronicals: Patents and Exclusivity 2015 [Internet]. Silver Springs (MD): United States (2015). Accessed May 27 2020.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses;JAMA Health Forum;2024-08-16

2. Orphan Drug Label Expansions: Analysis Of Subsequent Rare And Common Indication Approvals;Health Affairs;2024-01-01

3. Are Manufacturing Patents to Blame for Biosimilar Market Launch Delays?;Value in Health;2023-12

4. Life after patent: Drug price dynamics and cost-effectiveness analysis;2023-06-12

5. Drug discovery: Chaos can be your friend or your enemy;Managing the Drug Discovery Process;2023